Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
The disclosure provides compositions and methods for treating, ameliorating, and/or preventing a vaso-occlusive crisis (VOC) in a subject suffering from sickle cell disease (SCD). The disclosure also provides compositions and methods for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS). The disclosure provides A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13) or a composition comprising ADAMTS13 for treating, ameliorating, and/or preventing the VOC, or for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from ALI and/or ARDS.
1. A method for treating or preventing a vaso-occlusive crisis in a subject suffering from sickle cell disease (SCD), the method comprising administering to the SCD subject in need thereof a therapeutically effective amount of a composition comprising A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13).
2. The method of claim 1 , wherein the SCD subject is administered the composition comprising ADAMTS13 after symptoms of a vaso-occlusive crisis are present.
3. The method of claim 1 , wherein the SCD subject is administered the composition comprising ADAMTS13 before symptoms of a vaso-occlusive crisis are present.
4. The method of claim 1 , wherein administering the composition comprising ADAMTS13 to the SCD subject reduces at least one of inflammation, vasoconstriction, platelet aggregation, or a combination of any thereof as compared to a control subject or to observation of the SCD subject without the administration of said ADAMTS13 composition.
5. The method of claim 1 , wherein administering the composition comprising ADAMTS13 to the SCD subject results in at least one of improved survival, improved lung function, reduced organ damage, reduced pulmonary vascular leakage, or a combination of any thereof as compared to a control subject or to observation of the SCD subject without the administration of said ADAMTS13 composition.
6. The method of claim 1 , wherein administering the composition comprising ADAMTS13 to the SCD subject reduces and/or prevents at least one of impaired blood flow, blood coagulation, vascular inflammation, thrombosis, ischemic cell damage, or organ damage, or a combination of any thereof as compared to a control subject or to observation of the SCD subject without the administration of said ADAMTS13 composition.
7. The method of claim 1 , wherein administering the ADAMTS13 composition to the SCD subject reduces and/or prevents pain or severity of the pain as compared to a control subject or to observation of the SCD subject without the administration of said ADAMTS13 composition.
8. The method of claim 1 , wherein administering the ADAMTS13 composition to the SCD subject reduces the frequency of occurrence and/or duration of vaso-occlusive crisis (VOC) episodes as compared to a control subject or to observation of the SCD subject without the administration of said ADAMTS13 composition.
9. The method of claim 1 , wherein administering the ADAMTS13 composition to the SCD subject reduces expression, level, and/or activation of at least one of Vascular Cell Adhesion Molecule-1 (VCAM-1), Intercellular Adhesion Molecule 1 (ICAM-1), Phospho-Nuclear Factor- kappa B (P-NF-kB), Nuclear Factor-kappa B (NF-kB), Endothelin 1 (ET-1), Thromboxane synthase (TXAS), and Heme-oxygenase-1 (HO-1) in an organ of the SCD subject as compared to a control subject or to observation of the SCD subject without the administration of said ADAMTS13 composition.
10. The method of claim 1 , wherein administering the ADAMTS13 composition to the SCD subject increases the level of at least one of Hematocrit (Hct), Hemoglobin (Hb), mean corpuscular volume (MCV), and mean corpuscular hemoglobin (MCH) in the blood as compared to a control subject or to observation of the SCD subject without the administration of said ADAMTS13 composition.
11. The method of claim 1 , wherein administering the ADAMTS13 composition to the SCD subject reduces the level of at least one of cell hemoglobin concentration mean (CHCM), heterogeneity of red cell distribution (HDW), lactate dehydrogenase (LDH), and neutrophil numbers in the blood as compared to a control subject or to observation of the SCD subject without the administration of said ADAMTS13 composition.
12. The method of claim 1 , wherein the therapeutically effective amount of ADAMTS13 is from about 20 to about 6,000 international units per kilogram body weight, about 40 to about 4,000 international units per kilogram body weight, about 50 to about 3,000 international units per kilogram body weight, or 50 to about 500 international units per kilogram body weight.
13. The method of claim 1 , wherein the composition comprising ADAMTS13 is administered in a single bolus injection, monthly, every two weeks, weekly, twice a week, daily, every 12 hours, every eight hours, every six hours, every four hours, or every two hours.
14. The method of claim 1 , wherein the composition comprising ADAMTS13 is administered intravenously or subcutaneously.
15. The method of claim 1 , wherein the ADAMTS13 is recombinant ADAMTS13 .
16. The method of claim 1 , wherein the ADAMTS13 is plasma derived.
17. The method of claim 1 , wherein the subject is a mammal.
18. The method of claim 1 , wherein the subject is a human.
19. The method of claim 1 , wherein the composition is in a stable aqueous solution ready for administration.
20. The method of claim 1 , wherein the therapeutically effective amount of the composition comprising ADAMTS13 is administered to the subject within 48 hours after the onset of the vaso-occlusive crisis.
21. The method of claim 15 , wherein (a) the therapeutic amount is from about 10 to about 500 international units (IU) of ADAMTS13 activity per kilogram of the subject's body weight, and (b) the composition comprises a stable aqueous solution that is administered in a single bolus injection, monthly, every two weeks, weekly, twice a week, daily, or every 12 hours.
22. The method of claim 21 , wherein the therapeutic amount of ADAMTS13 is from about 35 to about 320 international units per kilogram.
23. The method of claim 15 , wherein (a) the therapeutic amount of ADAMTS13 is from about 10 to about 500 international units per kilogram and (b) the composition comprises a stable aqueous solution that is administered in a single bolus injection, daily, every 12 hours, every eight hours, every six hours, every four hours, or every two hours.
24. The method of claim 23 , wherein the therapeutic amount of ADAMTS13 is from about 35 to about 320 international units per kilogram.
25. The method of claim 23 , wherein the composition is administered within 48 hours, 24 hours, 12 hours, or 6 hours of the onset of the vaso-occlusive crisis (VOC).
26. The method of claim 21 , wherein administering the ADAMTS13 composition to the SCD subject reduces the duration or frequency of occurrence of vaso-occlusive crisis (VOC) compared to a control subject.
27. The method of claim 25 , wherein administering the ADAMTS13 composition to the SCD subject reduces the severity of a vaso-occlusive crisis (VOC) compared to a control subject.
28. The method of claim 26 , wherein the composition provides the subject with a protective effect against a vaso-occlusive crisis (VOC) comprising an improved lower level of each of a plurality of markers of inflammation, vasoconstriction, or platelet aggregation, wherein said markers are selected from Thromboxane synthase (TXAS), Endothelin 1 (ET-1), Vascular Cell Adhesion Molecule-1 (VCAM-1), Intercellular Adhesion Molecule 1 (ICAM-1), Heme-oxygenase-1 (HO-1), and the ratio of Phospho-Nuclear Factor-kappa B (P-NF-kB) to Nuclear Factor-kappa B (NF-kB).
29. The method of claim 27 , wherein the composition provides the subject with a protective effect against a vaso-occlusive crisis (VOC) comprising an improved lower level of each of a plurality of markers of inflammation, vasoconstriction, or platelet aggregation, wherein said markers are selected from Thromboxane synthase (TXAS), Endothelin 1 (ET-1), Vascular Cell Adhesion Molecule-1 (VCAM-1), Intercellular Adhesion Molecule 1 (ICAM-1), Heme-oxygenase-1 (HO-1), and the ratio of Phospho-Nuclear Factor-kappa B (P-NF-kB) to Nuclear Factor-kappa B (NF-kB).
30. The method of claim 28 , wherein the composition provides a lower level of all of said markers.
31. The method of claim 29 , wherein the composition provides a lower level of all of said markers.
32. The method of claim 26 , wherein the composition provides the subject with improved hematology parameters comprising a lower level of each of a plurality of said parameters selected from cell hemoglobin concentration mean (CHCM), heterogeneity of red cell distribution (HDW), lactate dehydrogenase (LDH), and neutrophil numbers.
33. The method of claim 27 , wherein the composition provides the subject with improved hematology parameters comprising a lower level of each of a plurality of said parameters selected from cell hemoglobin concentration mean (CHCM), heterogeneity of red cell distribution (HDW), lactate dehydrogenase (LDH), and neutrophil numbers.
34. The method of claim 28 , wherein the composition provides a lower level of all of said hematology parameters.
35. The method of claim 29 , wherein the composition provides a lower level of all of said hematology parameters.
36. The method of claim 26 , wherein the composition provides the subject with improved hematology parameters comprising a higher level of each of a plurality of said parameters selected from Hematocrit (Hct), Hemoglobin (Hb), mean corpuscular volume (MCV), and mean corpuscular hemoglobin (MCH).
37. The method of claim 27 , wherein the composition provides the subject with improved hematology parameters comprising a higher level of each of a plurality of said parameters selected from Hematocrit (Hct), Hemoglobin (Hb), mean corpuscular volume (MCV), and mean corpuscular hemoglobin (MCH).
38. The method of claim 36 , wherein the composition provides a higher level of all of said hematology parameters.
39. The method of claim 37 , wherein the composition provides a higher level of all of said hematology parameters.
40. The method of claim 28 , wherein said markers indicate an improvement associated with one or both of the lungs and kidneys of the SCD subject.
41. The method of claim 29 , wherein said markers indicate an improvement associated with one or both of the lungs and kidneys of the SCD subject.
42. The method of claim 32 , wherein said markers indicate an improvement associated with one or both of the lungs and kidneys of the SCD subject.
43. The method of claim 33 , wherein said markers indicate an improvement associated with one or both of the lungs and kidneys of the SCD subject.
44. The method of claim 35 , wherein said markers indicate an improvement associated with one or both of the lungs and kidneys of the SCD subject.
45. The method of claim 36 , wherein said markers indicate an improvement associated with one or both of the lungs and kidneys of the SCD subject.